FreeTender
Accepting bidsgrantUnited States

Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed)

Issued by National Institutes of Health · via Grants.gov — US federal funding opportunities

Published
18 Jun 2026
Closes
25 May 2029, 23:59 UTC
Reference
PAR-27-055
Location
United States
Sector
Healthcare & Pharma

Details

The Institutional Development Award (IDeA) program supports biomedical research capacity building in states that have historically received low levels of NIH funding. The Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) Notice of Funding Opportunity (NOFO) supports the expansion and sustainability of biomedical research centers in IDeA-eligible institutions. These centers will focus on building research capacity in broad scientific areas of strategic importance for the institutions. The goal of COBRE-E is to expand research capacity by growing the institutional faculty base and supporting research projects and core facilities in the new area. The objective of COBRE-S is to sustain the infrastructure by continuing the growth of the faculty base and consolidating research cores. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered. Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligibility is restricted to institutions that meet all the following criteria:In an IDeA-eligible state, commonwealth, or jurisdiction, which are Alaska, Arkansas, Delaware, Hawaii, Idaho, Kansas, Kentucky, Louisiana, Maine, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, Puerto Rico, Rhode Island, South Carolina, South Dakota, Vermont, West Virginia, and Wyoming; andAward doctoral degrees in health-related sciences or are independent biomedical research institutes/medical centers with ongoing biomedical research programs funded by the NIH or other federal agencies; andHold three or fewer active COBRE awards (except for COBRE Phase 3), including those in no-cost extension at the time of application submission. Applications will not be accepted from organizations that hold four or more active Phase 1, Phase 2, COBRE-D, COBRE-E, and COBRE-S awards, including those in no-cost extension.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

CFDA number(s): 93.859

Federal funding opportunity published on Grants.gov. Applications are submitted through Grants.gov — see the official listing.

Context for bidders

We hold 411 notices from National Institutes of Health, going back to May 2023 — 378 of them still open. They buy mostly in Healthcare & Pharma, Education & Training and Water & Environment. There are 369 open Healthcare & Pharma tenders in United States. This one closes in 970 days.

Before you bid on this tender

A quick checklist to help you decide whether to bid and prepare a compliant submission for this healthcare & pharma opportunity. Always verify the details on the official source.

  • Confirm the exact closing date and time (and time zone) on the official portal — deadlines are strict and can be revised by a corrigendum.
  • Read the full notice and every attached document, including the scope, specifications and any bill of quantities or terms of reference.
  • Check the eligibility criteria — prior similar experience, annual turnover, certifications and registrations — and make sure you qualify before investing effort.
  • Prepare any earnest-money deposit (EMD) or bid security and the required formats early; missing or wrongly-formatted documents are a common cause of rejection.
  • Note how bids must be submitted (online or physical), in what format, and whether a digital signature or portal registration is required.
  • Watch for corrigenda and clarifications right up to the deadline — requirements and dates can change.

More Healthcare & Pharma tenders

All Healthcare & Pharma tenders →

FreeTender mirrors this notice for reference. Verify the details and bid on the official portal.

Verify & apply on the official portal →